Biotech for less than cash value Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: RWReeves who started this subject	2/21/2003 12:39:31 PM
From: double-plus-good	Read Replies (1) of 684

Two bios falling to levels of cash on hand that make them worth watching IMO are NGEN and CRXL. NGEN currently trading for about 55% of cash on hand with no meaningful debt considerations that i have yet found. CRXL, a Dutch based antibody and vaccine outfit beginning to approach 65% market cap to cash holding levels. I am just starting to dig around on these two. Anyone with fundamental input please feel welcome to comment on these two. Should note that CRXL latest filing appears to be for the quarter ending Sept 2002. Most recent annual report is for 2001.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next